Calcitrene (Calcipotriene)
Brand Names: Calcitrene
Methodology & AI Transparency ⓘ
Calcitrene (Calcipotriene) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Marketed under the trade name Calcitrene (registered by Sun Pharmaceutical Industries, Inc., RxNorm 308865-B516725278), this prescription brand-name formulation contains Calcipotriene within the Vitamin D Analog therapeutic class.
- 2 Real-world patient consensus: Branded vitamin d analog presentation of Calcipotriene (Sun Pharmaceutical Industries, Inc.); generic reference: /meds/calcipotriene.
- 3 Typical cash cost range: Dispensing cost comparison spans $90.44 mail/discount cash up to $239.67 uninsured retail (federal NADAC $1.1381).
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Calcitrene (Calcipotriene) include application-site irritation (5%), nausea (8.7%), headache (8.3%).
Ask our AI Specialists anything about Calcitrene (Calcipotriene)
Calcitrene (Calcipotriene) Mechanism, CYP450 Pathways & DailyMed Monograph
Marketed under the trade name Calcitrene (registered by Sun Pharmaceutical Industries, Inc., RxNorm 308865-B516725278), this prescription brand-name formulation contains Calcipotriene within the Vitamin D Analog therapeutic class. Per 2024-05-09 DailyMed labeling (51672-5278), clinical use centers on .05 mg/g Ointment; 0.005% Bottle of Solution: Foam is indicated for the topical treatment of plaque psoriasis of the scalp and body in adults and pediatric patients 4.
At the receptor and enzymatic level, Calcitrene delivers Calcipotriene to execute vitamin d analog modulation with class-characteristic hepatorenal disposition. Specific to the Calcitrene commercial product (NDC 51672-5278, RxCUI 308865-B516725278), tablet/vehicle compounding registered by Sun Pharmaceutical Industries, Inc. standardizes delivery across .05 mg/g Ointment; 0.005% Bottle of Solution, contrasting $90.44 discount cash access against $239.67 walk-in retail pricing.
Pharmacokinetic profiling of Calcitrene (Calcipotriene) demonstrates an elimination half-life of Negligible circulating terminal half-life following local Calcitrene (Calcipotriene) application with < 5% transdermal or mucosal systemic uptake from Calcitrene (Calcipotriene) systemic bioavailability; clearance proceeds via local esterase/enzymatic cleavage of calcitrene (calcipotriene) with minimal hepatic cytochrome burden, reaching clinical onset within initial local symptom modulation in 30–90 minutes; full tissue response over 1–3 weeks (calcitrene (calcipotriene)).
Titration schedules for Calcitrene (Calcipotriene) (.05 mg/g Ointment → 0.005% Bottle of Solution → 0.005% Tube of Cream → 0.005% Tube of Ointment) require excluding confirmed ige-mediated allergy or cutaneous reaction to calcitrene (calcipotriene) (calcipotriene) components; uncompensated hepatic or renal insufficiency incompatible with calcitrene (calcipotriene) (.05 mg/g ointment) clearance; real-world patient logs highlight nausea (8.7% of reports), headache (8.3% of reports), dizziness (6.8% of reports) alongside a 84.00% Worth-It consensus.
Reconcile eGFR-adjusted medications before escalating Calcitrene (Calcipotriene) in polypharmacy regimens.
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Calcitrene (Calcipotriene) dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Confirmed IgE-mediated allergy or cutaneous reaction to Calcitrene (Calcipotriene) (Calcipotriene) components
- Uncompensated hepatic or renal insufficiency incompatible with Calcitrene (Calcipotriene) (.05 mg/g Ointment) clearance
Logged Side-Effect Incidence (18 Reports)
Calcitrene (Calcipotriene) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Calcitrene (Calcipotriene))
Human clinical trial evidence for Calcitrene (Calcipotriene) is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Calcitrene (Calcipotriene) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $1.1381/unit (~$34.14/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $239.67 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 18 Anonymous DotMD Community Micro-Logs | $90.44 / mo | View logs ↓ |
Calcitrene (Calcipotriene) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Calcitrene (Calcipotriene) RxNorm Concept ID | 308865-B516725278 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $1.1381 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $239.67 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $90.44 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 84.00% Worth It (18 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Calcitrene (Calcipotriene) Patient Community, Cohort Filters & Dosage Logs
Deterministic Calcitrene (Calcipotriene) reference combining NIH RxNorm (308865-B516725278), Medicaid NADAC ($1.1381/unit), and anonymous cohort outcomes (84% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Calcitrene (Calcipotriene) community threads and patient logs by age, biological sex, dosage, and treatment duration.